1. Home
  2. UVV vs GERN Comparison

UVV vs GERN Comparison

Compare UVV & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$54.38

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
GERN
Founded
1886
1990
Country
United States
United States
Employees
N/A
229
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
UVV
GERN
Price
$54.38
$1.61
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
167.6K
14.6M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
6.25%
N/A
EPS Growth
N/A
N/A
EPS
3.02
N/A
Revenue
$2,922,924,000.00
N/A
Revenue This Year
$0.67
$26.91
Revenue Next Year
$0.10
$43.75
P/E Ratio
$17.96
N/A
Revenue Growth
7.40
N/A
52 Week Low
$49.96
$1.04
52 Week High
$67.33
$2.01

Technical Indicators

Market Signals
Indicator
UVV
GERN
Relative Strength Index (RSI) 57.78 52.13
Support Level $54.16 $1.43
Resistance Level $56.29 $1.72
Average True Range (ATR) 0.98 0.07
MACD 0.18 -0.00
Stochastic Oscillator 90.70 50.00

Price Performance

Historical Comparison
UVV
GERN

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: